Summary
Boston Scientific Corporation (BSX) announced on January 18, 2011, the signing of a definitive merger agreement to acquire Atritech, Inc., a privately held medical device company. This acquisition is strategically significant as Atritech has developed a novel device aimed at closing the left atrial appendage. This procedure is designed for patients suffering from atrial fibrillation who are at increased risk of ischemic stroke. The transaction is anticipated to close in the first quarter of 2011, subject to customary closing conditions. This move signals Boston Scientific's commitment to expanding its portfolio in cardiovascular treatments, specifically addressing stroke prevention in a growing patient demographic. Investors should monitor the integration of Atritech's technology and its potential impact on BSX's future revenue and market position in the cardiac rhythm management and structural heart sectors.
Key Highlights
- 1Boston Scientific (BSX) is acquiring Atritech, Inc., a privately held medical device company.
- 2Atritech has developed a novel device to close the left atrial appendage.
- 3The acquired device targets patients with atrial fibrillation at risk for ischemic stroke.
- 4The acquisition is expected to close in the first quarter of 2011.
- 5The transaction is subject to customary closing conditions.
- 6This acquisition expands BSX's offerings in cardiovascular disease management.